FDA Approval Summary: Dabrafenib in Combination with Trametinib for <i>BRAF</i>V600E Mutation–Positive Low-Grade Glioma
Michael I. Barbato(United States Food and Drug Administration), Nicole Drezner(Center for Drug Evaluation and Research), Anup Amatya(Center for Drug Evaluation and Research), Barbara Scepura(Center for Drug Evaluation and Research), Banu S. Zolnik(Center for Drug Evaluation and Research), Harpreet Singh(United States Food and Drug Administration), Hong Zhao(Center for Drug Evaluation and Research), Richard Pazdur(United States Food and Drug Administration), Paul G. Kluetz(United States Food and Drug Administration), Martha Donoghue(Center for Drug Evaluation and Research), Stacy S. Shord(Center for Drug Evaluation and Research), Claudia P. Miller(Center for Drug Evaluation and Research), Jeannette Nashed(Center for Drug Evaluation and Research), Sachia G. Khasar(Center for Drug Evaluation and Research), Pallavi S. Mishra‐Kalyani(Center for Drug Evaluation and Research), Youwei Bi(Center for Drug Evaluation and Research), Raniya Ali Al-Matari(Center for Drug Evaluation and Research), Yangbing Li(Center for Drug Evaluation and Research), Yi Ren(Center for Drug Evaluation and Research), Diana Bradford(Center for Drug Evaluation and Research)
Cited by 70
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k